412 related articles for article (PubMed ID: 15001610)
1. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
[TBL] [Abstract][Full Text] [Related]
2. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
[TBL] [Abstract][Full Text] [Related]
3. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
Fernández-Rivera J; García R; Lozano F; Macías J; García-García JA; Mira JA; Corzo JE; Gómez-Mateos J; Rueda A; Sánchez-Burson J; Pineda JA
HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
Mora S; Zamproni I; Beccio S; Bianchi R; Giacomet V; Viganò A
J Clin Endocrinol Metab; 2004 Jan; 89(1):24-8. PubMed ID: 14715822
[TBL] [Abstract][Full Text] [Related]
5. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
6. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
[TBL] [Abstract][Full Text] [Related]
7. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
[TBL] [Abstract][Full Text] [Related]
8. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
[TBL] [Abstract][Full Text] [Related]
9. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
10. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors.
Tsai MS; Hung CC; Liu WC; Chen KL; Chen MY; Hsieh SM; Sheng WH; Sun HY; Shih TT
J Microbiol Immunol Infect; 2014 Apr; 47(2):109-15. PubMed ID: 23073318
[TBL] [Abstract][Full Text] [Related]
11. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
Fairfield WP; Finkelstein JS; Klibanski A; Grinspoon SK
J Clin Endocrinol Metab; 2001 May; 86(5):2020-6. PubMed ID: 11344201
[TBL] [Abstract][Full Text] [Related]
12. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population.
Pinto Neto LF; Ragi-Eis S; Vieira NF; Soprani M; Neves MB; Ribeiro-Rodrigues R; Miranda AE
J Clin Densitom; 2011; 14(4):434-9. PubMed ID: 22051092
[TBL] [Abstract][Full Text] [Related]
13. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.
Muhammad S; Sani MU; Okeahialam BN
Ann Afr Med; 2013; 12(1):24-8. PubMed ID: 23480991
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
Mora S; Sala N; Bricalli D; Zuin G; Chiumello G; Viganò A
AIDS; 2001 Sep; 15(14):1823-9. PubMed ID: 11579244
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
[TBL] [Abstract][Full Text] [Related]
17. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Mannazzu M; Falchi A; Sanna D; Mura MS; Madeddu G
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):290-301. PubMed ID: 18596668
[TBL] [Abstract][Full Text] [Related]
18. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
19. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
